Agilent Technologies, Inc.

LSE:0HAV Stock Report

Market Cap: US$38.0b

Agilent Technologies Valuation

Is 0HAV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HAV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0HAV ($134.73) is trading below our estimate of fair value ($160.81)

Significantly Below Fair Value: 0HAV is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HAV?

Key metric: As 0HAV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0HAV. This is calculated by dividing 0HAV's market cap by their current earnings.
What is 0HAV's PE Ratio?
PE Ratio29.5x
EarningsUS$1.29b
Market CapUS$37.98b

Price to Earnings Ratio vs Peers

How does 0HAV's PE Ratio compare to its peers?

The above table shows the PE ratio for 0HAV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.1x
ERGO Ergomed
46.7x14.2%UK£701.1m
GSK GSK
21.5x23.2%UK£53.9b
HVO hVIVO
7.7x-29.6%UK£133.7m
IQV IQVIA Holdings
24.7x13.5%US$34.7b
0HAV Agilent Technologies
29.5x8.2%US$38.0b

Price-To-Earnings vs Peers: 0HAV is expensive based on its Price-To-Earnings Ratio (29.5x) compared to the peer average (18x).

Price to Earnings Ratio vs Industry

How does 0HAV's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0HAV 29.5xIndustry Avg. 37.6xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0HAV is good value based on its Price-To-Earnings Ratio (29.5x) compared to the European Life Sciences industry average (37.6x).

Price to Earnings Ratio vs Fair Ratio

What is 0HAV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HAV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.5x
Fair PE Ratio28.5x

Price-To-Earnings vs Fair Ratio: 0HAV is expensive based on its Price-To-Earnings Ratio (29.5x) compared to the estimated Fair Price-To-Earnings Ratio (28.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HAV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$134.73
US$148.76
+10.4%
6.0%US$165.00US$135.00n/a17
Dec ’25US$137.97
US$148.64
+7.7%
6.0%US$165.00US$135.00n/a17
Nov ’25US$136.97
US$150.11
+9.6%
5.5%US$165.00US$135.00n/a17
Oct ’25US$146.04
US$148.10
+1.4%
6.6%US$165.00US$130.00n/a17
Sep ’25US$141.12
US$147.51
+4.5%
7.0%US$165.00US$130.00n/a17
Aug ’25US$142.12
US$141.35
-0.5%
6.6%US$155.00US$125.00n/a16
Jul ’25US$128.20
US$139.85
+9.1%
6.9%US$155.00US$125.00n/a16
Jun ’25US$131.04
US$141.12
+7.7%
7.2%US$155.00US$125.00n/a17
May ’25US$138.17
US$151.11
+9.4%
6.2%US$165.00US$130.00n/a18
Apr ’25US$146.70
US$147.06
+0.2%
7.5%US$165.00US$125.00n/a18
Mar ’25US$138.58
US$144.82
+4.5%
7.7%US$165.00US$125.00n/a17
Feb ’25US$132.12
US$139.59
+5.7%
8.1%US$165.00US$120.00n/a17
Jan ’25US$138.70
US$135.33
-2.4%
11.1%US$165.00US$100.00n/a18
Dec ’24US$128.23
US$132.86
+3.6%
10.2%US$151.00US$100.00US$137.9717
Nov ’24US$102.06
US$137.62
+34.8%
11.4%US$163.00US$105.00US$136.9717
Oct ’24US$111.68
US$139.68
+25.1%
10.3%US$163.00US$105.00US$146.0417
Sep ’24US$122.11
US$141.56
+15.9%
9.3%US$163.00US$110.00US$141.1217
Aug ’24US$123.09
US$143.19
+16.3%
9.1%US$163.00US$115.00US$142.1217
Jul ’24US$120.14
US$144.72
+20.5%
7.6%US$163.00US$126.00US$128.2017
Jun ’24US$116.59
US$147.29
+26.3%
7.9%US$170.00US$126.00US$131.0417
May ’24US$136.04
US$162.00
+19.1%
7.3%US$174.00US$127.00US$138.1717
Apr ’24US$137.87
US$163.13
+18.3%
7.0%US$174.00US$127.00US$146.7016
Mar ’24US$138.36
US$163.13
+17.9%
7.0%US$174.00US$127.00US$138.5816
Feb ’24US$153.24
US$162.50
+6.0%
6.8%US$170.00US$127.00US$132.1216
Jan ’24US$148.20
US$160.31
+8.2%
6.9%US$170.00US$127.00US$138.7016
Dec ’23US$156.01
US$159.19
+2.0%
6.9%US$170.00US$127.00US$128.2316

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 18:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/10/31
Annual Earnings2024/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Agilent Technologies, Inc. is covered by 43 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird
Ishan MajumdarBaptista Research